Synonyms: FRA, FR-alpha
Mirvetuximab (Anti-FOLR1) is a monoclonal antibody targeting FOLR1 (folate receptor 1). Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). MW: 145.2 KD
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Description |
Mirvetuximab (Anti-FOLR1) is a monoclonal antibody targeting FOLR1 (folate receptor 1). Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). MW: 145.2 KD
|
|---|
| CAS No. | 1453084-36-0 |
|---|---|
| Molecular Weight | 145.2 kDa |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT06890338 | RECRUITING | Drug: Carboplatin|Drug: Mirvetuximab Soravtansine|Drug: Beva | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; Neoadjuvant | AbbVie | 2025-11-21 | PHASE2 |
| NCT05887609 | RECRUITING | Drug: Mirvetuximab Soravtansine-gynx|Drug: Olaparib | Ovary Cancer; Peritoneal Cancer; Fallopian Tube Cancer | University of Colorado, Denver | 2023-10-03 | PHASE2 |
| NCT07059845 | RECRUITING | Drug: Mirvetuximab Soravtansine|Drug: Bevacizumab|Drug: Carb | Ovarian Cancer | AbbVie | 2025-11-13 | PHASE2 |
| NCT07218809 | RECRUITING | Drug: AZD5335|Drug: Mirvetuximab Soravtansine (MIRV)|Drug: P | Epithelial Ovarian Cancer | AstraZeneca | 2025-12-29 | PHASE3 |
| NCT07213804 | RECRUITING | Drug: Sofetabart Mipitecan|Drug: Paclitaxel|Drug: Topotecan| | Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Neoplasm Metastasis | Eli Lilly and Company | 2025-10-22 | PHASE3 |
| NCT07790939 | NOT_YET_RECRUITING | Epithelial Ovarian Cancer; Ovarian Cancer | Peking University Cancer Hospital & Institute | 2026-09-01 | EARLY_PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-09-01)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.